Mitochondrial diseases — MELAS / MERRF / Leigh syndrome / NARP / KSS / CPEO / LHON / Pearson / MNGIE / primary CoQ10 deficiency / TANGO2 / Barth syndrome
Large heterogeneous family of disorders of oxidative phosphorylation caused by mutations in mtDNA or nuclear DNA encoding the >1500 nuclear-encoded mitochondrial proteins or the 13 mtDNA-encoded proteins. Major syndromes: MELAS (Mitochondrial Encephalopathy with Lactic Acidosis and Stroke-like episodes — mtDNA m.3243A>G in MT-TL1; stroke-like episodes + cardiomyopathy + diabetes + sensorineural hearing loss); MERRF (m.8344A>G in MT-TK); LEIGH SYNDROME (subacute necrotizing encephalomyelopathy — multiple mtDNA + nuclear etiologies; infantile/childhood; often fatal); NARP (m.8993T>G in MT-ATP6); KEARNS-SAYRE SYNDROME (large mtDNA deletion; PEO + pigmentary retinopathy + cardiac conduction defects); CPEO; LHON (m.11778G>A in MT-ND4 most common; bilateral subacute vision loss in young adult males); PEARSON SYNDROME; MNGIE (TYMP); primary CoQ10 DEFICIENCY; TANGO2 deficiency; BARTH SYNDROME (TAFAZZIN/TAZ X-linked). HETEROPLASMY (% mutant mtDNA varies by tissue) is load-bearing for mtDNA disorders; maternal inheritance for mtDNA, Mendelian for nuclear. Standard of care: COENZYME Q10 supplementation (clinical use established); L-CARNITINE + B-VITAMINS (riboflavin B2, biotin) + CREATINE + antioxidants; ARGININE + CITRULLINE for MELAS stroke-like episodes; TAURINE for MELAS (Japan-approved). DISEASE-SPECIFIC APPROVALS: IDEBENONE (Raxone/Catena, Santhera Pharmaceuticals) EMA-approved 2015 for LHON; LUMEVOQ (lenadogene nolparvovec, GenSight Biologics) AAV gene therapy for LHON EMA pending; ELAMIPRETIDE (Forzinity, Stealth BioTherapeutics) FDA-APPROVED DECEMBER 2024 for BARTH SYNDROME — cardiolipin remodeling, first disease-modifier in Barth; TANGO2 B-vitamin cocktail (especially riboflavin) Lupski-lab landmark; MNGIE allogeneic HSCT. MEDICATIONS TO AVOID: VALPROATE (mitochondrial toxin, Alpers/POLG contraindication), AMINOGLYCOSIDES (mtDNA hearing-loss susceptibility), STATINS (variable), METFORMIN (lactate elevation in MELAS). Patient infrastructure: UMDF (umdf.org) + MitoAction + MitoCanada Foundation + Mito-Patients UK + AMMi + MitoExchange + NAMDC + Mitochondrial Medicine Society. **Hundredth deliberate non-elevation of community peptides — editorial centennial milestone.**
What changes during this transition
Mitochondrial diseases are among the MOST AGGRESSIVELY targeted condition axes in community peptide marketing — NMN, urolithin A, and CoQ10 stacks are routinely framed as 'mitochondrial support' or 'mitochondrial enhancement' in ways that collapse the distinction between general-population NAD+ biology and monogenic disorders of oxidative phosphorylation. The substrate here has to be sharper than most. The disease-modifying landscape is real, mature in parts, and structured around specific molecules — not the community peptide class. CoQ10 supplementation has long-established clinical use; L-carnitine, B-vitamins (especially riboflavin and biotin), creatine, and the antioxidant cluster are the supportive scaffold; arginine + citrulline is the load-bearing intervention for MELAS stroke-like episodes (IV arginine during acute MELAS SLE is established); taurine supplementation for MELAS is Japan-approved. Disease-specific approvals: IDEBENONE (Raxone/Catena, Santhera) is EMA-approved since 2015 for LHON at 900 mg/day on RHODOS, NOT FDA-approved for LHON (was FDA-approved for Friedreich ataxia 2013 then withdrawn). LUMEVOQ (GenSight Biologics) is the AAV gene-therapy for LHON MT-ND4 with REVERSE + RESCUE + REFLECT Phase 3 program — EMA approval pending after negative CHMP opinion 2024 with appeal ongoing. ELAMIPRETIDE (Forzinity, Stealth BioTherapeutics) was FDA-approved December 2024 for BARTH SYNDROME — first disease-modifier in Barth, cardiolipin-remodeling landmark. The TANGO2 deficiency B-vitamin cocktail (especially riboflavin) emerged from the Lupski-lab program and has been transformative — the editorial counter-example showing what real clinical evidence looks like when a vitamin cocktail actually addresses a monogenic disease. The medications-to-avoid thread is load-bearing safety: VALPROATE (mitochondrial toxin, Alpers/POLG contraindication, fatal hepatic decompensation), AMINOGLYCOSIDES (mtDNA hearing-loss susceptibility), STATINS (variable), METFORMIN (lactate elevation in MELAS). The community peptide class does not earn elevation. NMN is the editorially central case: it is the most-aggressively-marketed community peptide for 'mitochondrial enhancement,' and the substrate has to be honest in both directions. NAD+ biology in mitochondria IS real (complex I, SIRT3, PARP). The community framing reads this as 'NMN supports mitochondria, mitochondrial diseases are mitochondrial dysfunction, therefore NMN should help.' That substitution is the load-bearing error: monogenic disorders of oxidative phosphorylation are not the same biological problem as age-related NAD+ decline, and NMN-specific evidence in monogenic mitochondrial disease is absent in any phase of clinical investigation. Surfacing NMN as a discovery option for diagnosed mitochondrial disease would mislead. The GH-axis trio carries a metabolic-stress concern; tesamorelin Rule 6 non-propagation is sharpest. Semaglutide reaches MELAS-T2D cohorts through diabetology referral but the lactic-acidosis interaction with reduced caloric intake plus GI fluid loss is the load-bearing safety thread. This is the **100th deliberate non-elevation of community peptides — the editorial centennial milestone of the substrate program**.
Important caveat
Mitochondrial diseases are managed by mitochondrial medicine specialists (NAMDC centers in the US, equivalent European centers via Mito-Patients UK + AMMi networks) with neurology, cardiology, ophthalmology (LHON, NARP, KSS), audiology (MELAS sensorineural hearing loss), endocrinology (MELAS diabetes), and genetic counseling co-management. **HETEROPLASMY IS LOAD-BEARING** for mtDNA disorders — % mutant mtDNA varies by tissue, drives phenotypic severity and heritability; **MATERNAL INHERITANCE for mtDNA disorders** (MELAS, MERRF, NARP, LHON, KSS, CPEO, Pearson); **MENDELIAN INHERITANCE for nuclear-encoded forms** (most Leigh syndromes, MNGIE, primary CoQ10 deficiency, TANGO2, Barth X-linked). **NEWBORN SCREENING DETECTS TANGO2** + **SCAD/MCAD** — most mitochondrial diseases NOT detected. **STANDARD OF CARE — SUPPORTIVE**: **COENZYME Q10 supplementation** (clinical use established); **L-CARNITINE + B-VITAMINS** (riboflavin B2, biotin) + **CREATINE** + **antioxidants**; **ARGININE + CITRULLINE for MELAS stroke-like episodes** (IV arginine during acute MELAS SLE established); **TAURINE supplementation for MELAS — JAPAN-APPROVED**. **AGGRESSIVE SICK-DAY MANAGEMENT**: AVOID fasting, dehydration, infection. **DISEASE-SPECIFIC APPROVALS**: **IDEBENONE (RAXONE/CATENA, Santhera Pharmaceuticals) EMA-APPROVED 2015 for LHON** at 900 mg/day on RHODOS — **NOT FDA-approved for LHON** (was FDA-approved for Friedreich ataxia 2013 then withdrawn). **LUMEVOQ (lenadogene nolparvovec, GenSight Biologics)** AAV gene therapy for LHON MT-ND4 — **REVERSE + RESCUE + REFLECT Phase 3 program**; **EMA APPROVAL PENDING** (negative CHMP opinion 2024, appeal ongoing); intravitreal injection. **ELAMIPRETIDE (FORZINITY, Stealth BioTherapeutics) FDA-APPROVED DECEMBER 2024 for BARTH SYNDROME** — cardiolipin remodeling, FIRST disease-modifier in Barth. **TANGO2 B-VITAMIN COCKTAIL (especially riboflavin)** — Lupski-lab landmark. **MNGIE** — allogeneic HSCT can correct thymidine phosphorylase deficiency. **OMAVELOXOLONE (SKYCLARYS, Reata/Biogen) FDA February 2023 for FRIEDREICH ATAXIA** — FA mitochondrial-adjacent, cross-link batch 141. Investigational vatiquinone (Reata Phase 3 MOVE-FA); KH176 sonlicromanol (Khondrion Phase 2/3). **MEDICATIONS TO AVOID — LOAD-BEARING SAFETY**: **VALPROATE** — mitochondrial toxin, **ALPERS SYNDROME (POLG) CONTRAINDICATION**, fatal hepatic decompensation in undiagnosed POLG disease. **AMINOGLYCOSIDES** — mtDNA hearing-loss susceptibility (especially m.1555A>G). **STATINS** — variable interaction. **METFORMIN** — lactate elevation in MELAS. **PEDIATRIC LEIGH SYNDROME**: editorially sensitive — often fatal infantile/childhood with brainstem and basal-ganglia necrosis. **MELAS STROKE-LIKE EPISODES**: IV arginine during acute SLE is established practice — ED presentation with focal neurological deficit + lactic acidosis needs the MELAS letter, IV arginine protocol, and neurology. **KSS CARDIAC CONDUCTION DEFECTS**: progressive heart block — pacemaker thresholds drive cardiology surveillance. **LHON ACUTE PHASE**: time-sensitive ophthalmology referral. **PATIENT INFRASTRUCTURE**: **UMDF (umdf.org)** + **MitoAction** + **MitoCanada Foundation** + **Mito-Patients UK + AMMi (Italian)** + **MitoExchange** + **NAMDC** + **Mitochondrial Medicine Society**. **COMMUNITY PEPTIDES Tier 3**: **BPC-157** — pro-angiogenic VEGF/eNOS uncharacterized in mitochondrial biology. **NMN — EDITORIALLY CENTRAL**: **the most-aggressively-marketed community peptide for 'mitochondrial enhancement.'** NAD+ biology in mitochondria IS real (complex I, SIRT3, PARP mtDNA repair), but NMN-specific evidence in MONOGENIC mitochondrial disease is ABSENT in any phase of clinical investigation. **NEVER substitutes for established mitochondrial-disease management**. **GH-AXIS TRIO** (CJC-1295, ipamorelin, tesamorelin): GH/IGF-1 anabolism increases metabolic demand and substrate flux through diseased OXPHOS machinery; pediatric Leigh growth-retardation context is a metabolic-stress concern, not a growth-promotion opportunity. **TESAMORELIN Rule 6 SHARPEST** — HIV-LD FDA label does NOT propagate to any mitochondrial disease. **SEMAGLUTIDE in adult MELAS-T2D**: GLP-1-induced appetite suppression + vomiting + diarrhea + de facto fasting are EXACTLY the metabolic stressors mitochondrial sick-day management is engineered to prevent; **MELAS lactic-acidosis interaction with reduced caloric intake plus GI fluid loss is the load-bearing safety thread**. **NO Juno library peptide is surfaced as a mitochondrial-disease discovery card — 100TH DELIBERATE NON-ELEVATION (EDITORIAL CENTENNIAL MILESTONE)**. **RED FLAGS**: focal neurological deficit + lactic acidosis in known MELAS patient (acute SLE — IV arginine + neurology); new bilateral subacute vision loss in young adult male (LHON — time-sensitive ophthalmology); cardiac conduction symptoms in known KSS (pacemaker evaluation); refractory seizures + hepatic failure on valproate in undiagnosed encephalopathy (POLG/Alpers — STOP valproate); recurrent metabolic crises with rhabdomyolysis + arrhythmia in pediatrics (TANGO2 — B-vitamin cocktail).
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.